CareDx, Inc. regulatory filings document the public-company record for a Nasdaq-listed precision medicine company serving transplant patients and caregivers. The company’s 8-K and proxy materials cover operating and financial results for testing services, patient and digital solutions, laboratory products, and clinical or regulatory disclosures tied to non-invasive molecular testing for organ transplantation.
CareDx filings also address material agreements, capital-structure matters for its common stock, shareholder voting items, board governance, executive compensation, inducement and other equity awards, and officer-role changes. Other-event disclosures include governance and legal-contingency materials, including shareholder derivative litigation settlement documents when filed.
CareDx, Inc. filed a current report to furnish a press release announcing its preliminary unaudited financial results for the quarter and year ended December 31, 2025. The press release, dated January 12, 2026, is included as Exhibit 99.1 to the report and is incorporated by reference.
The company states that this information is being furnished under the rules for current reports and is not deemed “filed” for purposes of certain liability provisions of the Exchange Act, nor automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced.
CareDx, Inc. director Michael Goldberg reported receiving an automatic quarterly grant of common stock as part of his non-employee director compensation. On January 6, 2026, he was awarded 1,492 shares of CareDx common stock at a reported price of $0 per share, reflecting equity paid in lieu of cash fees under the company’s Outside Director Compensation Policy. Following this grant, he beneficially owned 157,461 shares of CareDx common stock held directly.
CareDx, Inc. reports that a U.S. federal court has granted preliminary approval of a proposed settlement of a shareholder derivative lawsuit titled Edelman, et al. v. Bickerstaff, et al. The company previously reached an agreement in principle to resolve this case, and on December 9, 2025, the U.S. District Court for the Northern District of California issued an order preliminarily approving the settlement.
The Court also approved the form of notice to shareholders and scheduled a hearing on June 30, 2026 to consider whether to grant final approval of the proposed settlement. CareDx has filed the notice of pendency and proposed settlement and the full stipulation and agreement of compromise, settlement, and release as exhibits to this report.
CareDx, Inc. is updating how shareholders elect its directors. The board amended and restated the company’s bylaws to replace the prior plurality standard with a majority voting standard for uncontested director elections. A director nominee will now be elected only if the votes cast “for” exceed the votes cast “against,” while abstentions and broker non-votes are not counted as votes cast. In contested elections, the company will continue to use a plurality standard.
The board also adopted a director resignation policy. Any incumbent director in an uncontested election who does not receive at least a majority of the votes cast must promptly submit their resignation. The Governance and Nominating Committee will review the resignation and make a recommendation, and within 90 days after certification of the election results the board will decide whether to accept it and publicly disclose its decision.
CareDx (CDNA): The company’s Secretary and General Counsel reported an open-market sale of common stock. On 11/07/2025, the insider sold 2,688 shares at an average price of $15.5219 (code S). Following the transaction, the insider beneficially owns 105,218 shares, held directly. The sale was executed under a Rule 10b5-1 trading plan adopted on September 4, 2025.
CareDx (CDNA) insider filing: The company’s Secretary and General Counsel reported an automatic share withholding tied to restricted stock unit vesting. On 11/06/2025, 2,152 shares of common stock were withheld at $15.01 under transaction code F to satisfy tax obligations, as stated in the footnote. Following this administrative transaction, the insider beneficially owns 107,906 shares, held directly.
CareDx, Inc. filed a Form S-8 to register common stock for employee equity plans. The filing registers 1,600,000 additional shares of common stock issuable under the CareDx, Inc. 2024 Equity Incentive Plan (as amended) and 350,000 shares issuable under the CareDx, Inc. 2025 Inducement Equity Incentive Plan.
The company incorporates by reference its Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Exchange Act reports. The filing also outlines Delaware-law indemnification provisions for directors and officers and includes customary exhibits such as the legal opinion, auditor consent, the inducement plan, and the filing fee table.
CareDx, Inc. reported stronger quarterly results for the three months ended September 30, 2025. Revenue rose to $100.1 million from $82.9 million a year ago, driven by testing services ($72.2 million), products ($12.5 million), and patient and digital solutions ($15.4 million). The company posted net income of $1.7 million (diluted EPS $0.03), compared with a net loss of $10.6 million in the prior-year period.
Year‑to‑date, revenue reached $271.4 million with a net loss of $17.2 million. Cash and cash equivalents were $91.4 million and short‑term marketable securities were $102.8 million as of September 30, 2025. The company repurchased 5.0 million shares for a total of $75.6 million under its February and May 2025 programs, and had $24.4 million remaining under the May authorization. CareDx recorded an accrued litigation settlement expense of $20.25 million related to a securities class action, with $14.9 million in expected insurance proceeds recorded in prepaid assets. In the Lanham Act case against Natera, the appellate court affirmed liability and damages; no receivable was recorded. Management noted a material weakness in internal control remained unremediated as of September 30, 2025.
CareDx, Inc. filed a current report to furnish a press release announcing its financial results for the quarter ended September 30, 2025. The company issued the press release on November 4, 2025 and attached it as Exhibit 99.1.
The information about these quarterly results is being furnished under the rules for results of operations and Regulation FD disclosure, and is expressly stated not to be treated as filed for liability purposes or automatically incorporated into other securities law filings. CareDx also notes that the press release is current as of November 4, 2025 and that it does not undertake to update this material.
CareDx, Inc. (CDNA) reported an insider Form 4 for its Secretary and General Counsel. On 11/01/2025, an F-code transaction reflected 2,872 shares withheld to cover taxes upon RSU vesting at a price of $14.77 per share. Following the transaction, the officer beneficially owns 110,058 shares, held directly.
The filing notes the shares were withheld by the issuer to satisfy tax withholding obligations tied to vested restricted stock units.